Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)
Close on Nov 18, 2026Market cap $528.94MP/E –Yield –
Myriad Genetics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Myriad Genetics's operating cash flow for the twelve months ending Jun 30, 2026 was $7.70M. For fiscal 2025 it was $1.80M. Over ten years it grew -37.3% a year on average. The highest annual figure on record is $190.20M in fiscal 2014.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.80M | – |
| FY2024 | Dec 31, 2024 | -$8.70M | – |
| FY2023 | Dec 31, 2023 | -$110.90M | – |
| FY2022 | Dec 31, 2022 | -$106.30M | -275.1% |
| FY2020 | Jun 30, 2020 | $60.70M | -27.5% |
| FY2019 | Jun 30, 2019 | $83.70M | -27.8% |
| FY2018 | Jun 30, 2018 | $115.90M | +9.1% |
| FY2017 | Jun 30, 2017 | $106.20M | -36.1% |
| FY2016 | Jun 30, 2016 | $166.30M | +18.4% |
| FY2015 | Jun 30, 2015 | $140.50M | -26.1% |
| FY2014 | Jun 30, 2014 | $190.20M | +9.4% |
| FY2013 | Jun 30, 2013 | $173.90M | +22.6% |
| FY2012 | Jun 30, 2012 | $141.80M | +8.4% |
| FY2011 | Jun 30, 2011 | $130.83M | -15.6% |
| FY2010 | Jun 30, 2010 | $155.09M | +84.5% |
| FY2009 | Jun 30, 2009 | $84.04M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$8.30M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$15.70M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $10.60M | +60.6% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $21.10M | +2914.3% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$13.60M | -623.1% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$16.30M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $6.60M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $700.00K | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $2.60M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$18.60M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$54.70M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$22.10M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$900.00K | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$33.20M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$7.30M | -124.3% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$2.80M | -116.7% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$49.70M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$46.50M | -394.3% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $30.00M | -4.8% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $16.80M | +154.5% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$1.90M | -105.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $15.80M | +102.6% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $31.50M | -34.2% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $6.60M | -42.6% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $37.80M | +14.5% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $7.80M | -66.8% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $47.90M | +30.9% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $11.50M | -72.0% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $33.00M | +5.1% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $23.50M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $36.60M | -4.9% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $41.10M | -10.5% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $31.40M | -39.7% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$2.90M | -109.7% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $38.50M | -24.5% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $45.90M | +53.5% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $52.10M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $29.80M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $51.00M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $29.90M | – |
See a number that looks wrong?